Field comparison of canine NSAIDs Firocoxib and Deracoxib

International Journal of Applied Research in Veterinary Medicine

Volumn 8, Issue 2, 2010, Pages 114-123

  Ryan, William G ^a   Carithers, Doug ^b   Moldave, Katherine ^c   Bell, Margie ^d  

^a Ryan Mitchell Associates   (United States)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c AlcheraBio LLC   (United States)

^d ClinDataServices   (United States)

Author keywords

Deracoxib; Firocoxib; Musculoskeletal disorders; Osteoarthritis

Indexed keywords

EID: 84877979249     PISSN: 15422666     EISSN: 1559470X     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Hanson PD, Brooks KC, Case J, et al. Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. Vet Ther 2006;7:127-140.
2. Roberts ES, Van Lare KA, Marable BR, et al. Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. J Vet Pharmacol Therap 2008; 32:329-337.
3. Gierse JK, Staten NR, Casperson GF, et al. Cloning, expression, and selective inhibition of canine cyclooxygenase-1 and cyclooxygenase-2. Vet Ther 2002;3: 270-280.
4. McCann ME, Andersen DR, Zhang D, et al. In vitro effects and in vivo efficacy of a novel cyclooxygenase-2 inhibitor in dogs with experimentally induced synovitis. Am J Vet Res 2004;65:503-512.
5. Millis DE, Weigel JP, Moyers T, Buonomo FC. The effect of Deracoxib, a new COX-2 inhibitor, on the prevention of lameness induced by chemical synovitis in dogs. Vet Ther 2002; 3:453-64.
6. Hazewinkel HA, van den Brom WE, Theyse LF, et al. Comparison of the effects of firocoxib, carprofen and vedaprofen in a sodium urate crystal induced synovitis model of arthritis in dogs. Res Vet Sci 2008; 84:74-79.
7. Pollmeier M, Toulemonde C, Fleishman C, et al. Clinical evaluation of firocoxib and carprofen for the treatment of dogs with osteoarthritis. Vet Rec 2006;159:547-551.
8. Innes JF, Clayton J, Lascelles BD. Review of the safety and efficacy of long-term NSAID use in the treatment of canine osteoarthritis. Vet Rec 2010;166:226-230.
9. Ryan WG, Moldave K, Carithers D. Switching NSAIDs in practice: insights from the Previcox (firocoxib) Experience Trial. Vet Ther 2007;8:263-271.
10. Clayton HM. The force plate: established technology, new applications. Vet J. 2005;169:15-16.
11. Quinn MM, Keuler NS, Lu Y, et al. Evaluation of agreement between numerical rating scales, visual analogue scoring scales, and force plate gait analysis in dogs. Vet Surg. 2007;36:360-367.
12. Wiseman ML, Nolan AM, Reid J, et al. Preliminary study on owner-reported behaviour changes associated with chronic pain in dogs. Vet Rec 2001;149:423-424.
13. Brown DC, Boston RC, Coyne JC, et al. Ability of the canine brief pain inventory to detect response to treatment in dogs with osteoarthritis. J Am Vet Med Assoc 2008;233:1278-1283.
14. Food and Drug Administration, Center for Veterinary Medicine, Freedom of Information Summary, Supplementary NADA 141-203, Deramaxx Chewable Tablets, Approval Date Feb 11, 2003.
15. Ryan WG, Moldave K, Carithers D. Clinical effectiveness and safety of a new NSAID, firocoxib: a 1,000 dog study. Vet Ther 2006; 7:119-126
16. Lees P, Landoni MF, Giraudel J, et al. Pharmacodynamics and pharmacokinetics of non-steroidal anti-inflammatory drugs in species of veterinary interest. J vet Pharmacol Therap 2004; 27:479-490.